Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $215.00

Krystal Biotech (NASDAQ:KRYS) had its target price increased by Citigroup from $206.00 to $215.00 in a report released on Thursday,Benzinga reports. Citigroup currently has a neutral rating on the stock.

Several other research analysts have also commented on the company. Chardan Capital lifted their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a research report on Thursday. Finally, HC Wainwright reiterated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Wednesday. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $210.00.

Krystal Biotech Stock Up 2.9 %

Shares of NASDAQ KRYS opened at $187.86 on Thursday. Krystal Biotech has a fifty-two week low of $107.50 and a fifty-two week high of $219.34. The business has a 50 day moving average price of $157.85 and a two-hundred day moving average price of $175.28. The firm has a market cap of $5.41 billion, a PE ratio of 62.83 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. Krystal Biotech’s quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.30 EPS. On average, analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 14.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Several hedge funds have recently added to or reduced their stakes in the business. US Bancorp DE raised its stake in Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company’s stock valued at $161,000 after acquiring an additional 82 shares in the last quarter. Summit Investment Advisors Inc. raised its stake in Krystal Biotech by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company’s stock valued at $407,000 after acquiring an additional 82 shares in the last quarter. Crossmark Global Holdings Inc. raised its stake in Krystal Biotech by 5.5% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock valued at $362,000 after acquiring an additional 121 shares in the last quarter. Envestnet Asset Management Inc. raised its stake in Krystal Biotech by 1.1% during the 4th quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company’s stock valued at $1,822,000 after acquiring an additional 121 shares in the last quarter. Finally, Perigon Wealth Management LLC raised its stake in Krystal Biotech by 1.5% during the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company’s stock valued at $1,200,000 after acquiring an additional 123 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).